Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 7
2004 3
2005 7
2006 4
2007 5
2008 4
2009 11
2010 14
2011 17
2012 8
2013 12
2014 12
2015 9
2016 10
2017 5
2018 14
2019 9
2020 18
2021 18
2022 18
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Ahmadi T, Ukropec J, Kampfenkel T, Schecter JM, Qiu Y, Amin H, Vermeulen J, Carson R, Sonneveld P; APOLLO Trial Investigators. Dimopoulos MA, et al. Among authors: baldini l. Lancet Oncol. 2021 Jun;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5. Lancet Oncol. 2021. PMID: 34087126 Clinical Trial.
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
Dimopoulos MA, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li J, Salman Z, Graef T, Buske C; iNNOVATE Study Group and the European Consortium for Waldenström’s Macroglobulinemia. Dimopoulos MA, et al. N Engl J Med. 2018 Jun 21;378(25):2399-2410. doi: 10.1056/NEJMoa1802917. Epub 2018 Jun 1. N Engl J Med. 2018. PMID: 29856685 Free article. Clinical Trial.
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Dimopoulos MA, Terpos E, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Baldini L, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Kampfenkel T, Liu W, Wang J, Kosh M, Tran N, Carson R, Sonneveld P. Dimopoulos MA, et al. Among authors: baldini l. Lancet Haematol. 2023 Oct;10(10):e813-e824. doi: 10.1016/S2352-3026(23)00218-1. Lancet Haematol. 2023. PMID: 37793772 Clinical Trial.
Polarized x-rays from a magnetar.
Taverna R, Turolla R, Muleri F, Heyl J, Zane S, Baldini L, González-Caniulef D, Bachetti M, Rankin J, Caiazzo I, Di Lalla N, Doroshenko V, Errando M, Gau E, Kırmızıbayrak D, Krawczynski H, Negro M, Ng M, Omodei N, Possenti A, Tamagawa T, Uchiyama K, Weisskopf MC, Agudo I, Antonelli LA, Baumgartner WH, Bellazzini R, Bianchi S, Bongiorno SD, Bonino R, Brez A, Bucciantini N, Capitanio F, Castellano S, Cavazzuti E, Ciprini S, Costa E, De Rosa A, Del Monte E, Di Gesu L, Di Marco A, Donnarumma I, Dovčiak M, Ehlert SR, Enoto T, Evangelista Y, Fabiani S, Ferrazzoli R, Garcia JA, Gunji S, Hayashida K, Iwakiri W, Jorstad SG, Karas V, Kitaguchi T, Kolodziejczak JJ, La Monaca F, Latronico L, Liodakis I, Maldera S, Manfreda A, Marin F, Marinucci A, Marscher AP, Marshall HL, Matt G, Mitsuishi I, Mizuno T, Ng SC, O'Dell SL, Oppedisano C, Papitto A, Pavlov GG, Peirson AL, Perri M, Pesce-Rollins M, Pilia M, Poutanen J, Puccetti S, Ramsey BD, Ratheesh A, Romani RW, Sgrò C, Slane P, Soffitta P, Spandre G, Tavecchio F, Tawara Y, Tennant AF, Thomas NE, Tombesi F, Trois A, Tsygankov SS, Vink J, Wu K, Xie F. Taverna R, et al. Among authors: baldini l. Science. 2022 Nov 11;378(6620):646-650. doi: 10.1126/science.add0080. Epub 2022 Nov 3. Science. 2022. PMID: 36356124
Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort.
Cattaneo D, Bucelli C, Marchetti A, Lionetti M, Fermo E, Bellani V, De Magistris C, Maeda A, Marella A, Primignani M, Consonni D, Gianelli U, Neri A, Baldini L, Bolli N, Iurlo A. Cattaneo D, et al. Among authors: baldini l. Ann Hematol. 2023 Jun;102(6):1409-1420. doi: 10.1007/s00277-023-05217-2. Epub 2023 Apr 20. Ann Hematol. 2023. PMID: 37079068 Review.
What Is New in the Treatment of Smoldering Multiple Myeloma?
Bolli N, Sgherza N, Curci P, Rizzi R, Strafella V, Delia M, Gagliardi VP, Neri A, Baldini L, Albano F, Musto P. Bolli N, et al. Among authors: baldini l. J Clin Med. 2021 Jan 22;10(3):421. doi: 10.3390/jcm10030421. J Clin Med. 2021. PMID: 33499196 Free PMC article. Review.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Clinical Trial.
182 results